```
=> file caplus
FILE 'CAPLUS' ENTERED AT 16:44:07 ON 26 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Jul 2007  VOL 147 ISS 5
FILE LAST UPDATED: 25 Jul 2007  (20070725/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d que
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3           10 SEA FILE=REGISTRY SSS FUL L1
L4            2 SEA FILE=CAPLUS L3


=> d l4 1-2 ibib abs hitstr

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:857171  CAPLUS
DOCUMENT NUMBER:          141:332223
TITLE:                    Preparation of heterocyclic bicyclic compounds as NR2B
                          receptor antagonists
INVENTOR(S):              Ando, Kazuo; Kawai, Makoto; Kawamura, Mitsuhiro;
                          Matsumizu, Miyako; Morita, Asato; Sakurada, Isao
PATENT ASSIGNEE(S):       Pfizer Japan, Inc., Japan
SOURCE:                   U.S. Pat. Appl. Publ., 36 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE       APPLICATION NO.         DATE
     ---------------      ----   --------   --------------------    --------
     US 2004204409         A1    20041014   US 2004-816700          20040402
```

CA 2521907	A1	20041021	CA 2004-2521907		20040401
WO 2004089366	A1	20041021	WO 2004-IB1177		20040401
WO 2004089366	A8	20051027			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1615636	A1	20060118	EP 2004-725125		20040401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004009241	A	20060328	BR 2004-9241		20040401
JP 2006522794	T	20061005	JP 2006-506485		20040401
PRIORITY APPLN. INFO.:			US 2003-461918P	P	20030410
			WO 2004-IB1177	W	20040401

OTHER SOURCE(S): CASREACT 141:332223; MARPAT 141:332223

GI



I

AB Title compds. I [R1-2 = H, halo, alkyl, alkoxy, etc.; X = bond, alkylene, etc.; A = bicyclic, aromatic, (un)saturated heterocyclic ring, etc.; B = Ph, heteroaryl, etc.] are prepared For instance, N-[(2-benzyl-1H-indol-5-yl)methyl]-4-hydroxybenzamide (II)is prepared in 2 steps from (2-benzyl-1H-indol-5-yl)carbonitrile. II has Ki = 2 nM for the NR2B receptor. I is useful for the treatment of disease conditions caused by over activation of NMDA NR2B receptor, e.g., pain.

IT 773883-79-7P 773883-80-0P 773883-81-1P
773883-91-3P 773883-95-7P 773883-97-9P
773883-98-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)

RN 773883-79-7 CAPLUS

CN Benzamide, 4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-80-0 CAPLUS

CN Benzamide, 4-hydroxy-N-[[2-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-81-1 CAPLUS
CN Benzamide, 4-hydroxy-N-[[2-(hydroxyphenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-91-3 CAPLUS
CN Benzamide, N-[[2,3-dihydro-2-oxo-3-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 773883-95-7 CAPLUS
CN Benzamide, N-[[2-[(2-fluorophenyl)methyl]-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 773883-97-9 CAPLUS
CN Benzamide, 4-hydroxy-N-[[2-methyl-1-(2-phenylethyl)-1H-benzimidazol-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-98-0 CAPLUS
CN Benzamide, 3-fluoro-4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



IT 773884-10-9P 773884-11-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)
RN 773884-10-9 CAPLUS
CN Benzamide, 4-hydroxy-N-[[2-(2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773884-11-0 CAPLUS
CN Benzamide, N-[(2-benzoyl-1H-benzimidazol-5-yl)methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:747806 CAPLUS
DOCUMENT NUMBER: 135:273164
TITLE: Preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors
INVENTOR(S): Washburn, William N.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074835	A1	20011011	WO 2001-US10093	20010329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002052326	A1	20020502	US 2001-791186		20010223
US 6555519	B2	20030429			
CA 2404376	A1	20011011	CA 2001-2404376		20010329
EP 1268503	A1	20030102	EP 2001-922841		20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004500417	T	20040108	JP 2001-572524		20010329
PRIORITY APPLN. INFO.:			US 2000-193308P	P	20000330
			WO 2001-US10093	W	20010329

OTHER SOURCE(S): MARPAT 135:273164

GI



I



II

AB Glycosides. I wherein n is 0-2; A is substituted aryl or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO2; R1 is H, alkoxy, alkyl, aryl, arylalkyl, amide, amine, halogen; were prepared as SGLT2 inhibiting agents. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. Thus, glycoside II was prepared as antidiabetic and hypolipidemic agent and SGLT2 inhibitor (no data).

IT 363136-19-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors)

RN 363136-19-0 CAPLUS
CN Benzamide, N-(1H-benzimidazol-5-ylmethyl)-2-(β-D-glucopyranosyloxy)-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall
FILE 'USPATFULL' ENTERED AT 16:44:47 ON 26 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:44:47 ON 26 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 10 SEA FILE=REGISTRY SSS FUL L1
L5 3 SEA L3

=> d l5 1-3 ibib abs hitstr

L5 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:261907 USPATFULL
TITLE: Bicyclic compounds as NR2B receptor antagonists
INVENTOR(S): Ando, Kazuo, Aichi-ken, JAPAN

Kawai, Makoto, Aichi-ken, JAPAN
Kawamura, Mitsuhiro, Aichi-ken, JAPAN
Matsumizu, Miyako, Aichi-ken, JAPAN
Morita, Asato, Aichi-ken, JAPAN
Sakurada, Isao, Aichi-ken, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004204409	A1	20041014
APPLICATION INFO.:	US 2004-816700	A1	20040402 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-461918P	20030410 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 3057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a compound of the formula (I): ##STR1##

wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom or the like; X represents a covalent bond or the like: A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms; or the like: B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms or the like:

These compounds are useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 773883-79-7P 773883-80-0P 773883-81-1P
773883-91-3P 773883-95-7P 773883-97-9P
773883-98-0P
(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)
RN 773883-79-7 USPATFULL
CN Benzamide, 4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-80-0 USPATFULL
CN Benzamide, 4-hydroxy-N-[[2-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-81-1 USPATFULL
CN Benzamide, 4-hydroxy-N-[[2-(hydroxyphenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-91-3 USPATFULL
CN Benzamide, N-[[2,3-dihydro-2-oxo-3-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 773883-95-7 USPATFULL
CN Benzamide, N-[[2-[(2-fluorophenyl)methyl]-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 773883-97-9 USPATFULL
CN Benzamide, 4-hydroxy-N-[[2-methyl-1-(2-phenylethyl)-1H-benzimidazol-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-98-0 USPATFULL
CN Benzamide, 3-fluoro-4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



IT 773884-10-9P 773884-11-0P
(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)
RN 773884-10-9 USPATFULL
CN Benzamide, 4-hydroxy-N-[[2-(2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773884-11-0 USPATFULL
CN Benzamide, N-[(2-benzoyl-1H-benzimidazol-5-yl)methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2002:99425 USPATFULL
TITLE: O-glucosylated benzamide SGLT2 inhibitors and method
INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052326	A1	20020502
	US 6555519	B2	20030429
APPLICATION INFO.:	US 2001-791186	A1	20010223 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193308P	20000330 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 1420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

wherein

n is 0, 1 or 2;

A is ##STR2##

or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO.sub.2, bearing substituents R.sup.3 and R.sup.4;

and R.sup.1 to R.sup.4 are as defined herein.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 363136-19-0P
(preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors)
RN 363136-19-0 USPATFULL
CN Benzamide, N-(1H-benzimidazol-5-ylmethyl)-2-(β-D-glucopyranosyloxy)-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 3 USPAT2 on STN

ACCESSION NUMBER:	2002:99425 USPAT2
TITLE:	O-glucosylated benzamide SGLT2 inhibitors and method
INVENTOR(S):	Washburn, William N., Titusville, NJ, United States
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6555519	B2	20030429	
APPLICATION INFO.:	US 2001-791186		20010223	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-193308P	20000330	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Henley, III, Raymond

10/816,700

LEGAL REPRESENTATIVE: Kilcoyne, John M., Provoost, Jonathan N.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

wherein

n is 0, 1 or 2;

A is ##STR2##

or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO.sub.2, bearing substituents R.sup.3 and R.sup.4;

and R.sup.1 to R.sup.4 are as defined herein.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 363136-19-0P
(preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors)
RN 363136-19-0 USPAT2
CN Benzamide, N-(1H-benzimidazol-5-ylmethyl)-2-(β-D-glucopyranosyloxy)-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>